OCS - Oculis AG Profit before interest, taxes and amortization

Brandmark of Oculis Holding (OCS)

Biotech development relies on the results of ophthalmological drug trials and sufficient R&D capital. Prospects depend on the commercial success of drops for diabetic edema and FDA approval. EBITDA visualizes the cash flow, where the 0.00 level serves as a critical mark. Oaktree Specialty Lending (OCS) innovations are transforming retinal therapy, creating comfortable treatment methods through deep drug penetration.

Profit before payment of interest, taxes and amortization: Oculis Holding (OCS) for 11/23/2025 - 11/13/2026

Summary analytical data breakdowns for Oculis Holding (OCS)

- market value and analyst target forecast:
Market Price Oculis|OCS - Analyst Consensus Forecast
- market capitalization statistics:
Market Value Oculis|OCS - Total Company Value
- book capitalization data:
Net Assets per Share Oculis|OCS - Company Book Value|Market-to-Book Ratio oculis.com|OCS - Company Total Assets
- debt level and financial liquidity data:
Total Debt to Capital Oaktree Specialty Lending|OCS - Long-Term Debt to Equity|Short-Term Debt to Capital Oculis AG|OCS - Company Total Debt|Debt to Book Capital Oculis|OCS - Company Long-Term Debt|Company Short-Term Loans and Borrowings Oculis|Immediate Liquidity oculis.com
- company profitability and valuation multiples indicators:
OCS - Net Profit|Expected Net Profit Oaktree Specialty Lending|OCS - Price to Earnings Ratio|Future Price to Earnings Multiple oculis.com|OCS - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Oculis|OCS - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Oculis|OCS - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months oculis.com|OCS - Earnings growth in current year|Expected earnings per share growth for next year Oaktree Specialty Lending
Fundamental company valuation:Oaktree Specialty Lending OCS
Original product of Oculis Holding

Absolute operating profit reflects the business's actual ability to generate cash flow before interest and taxes. This metric measures core operational efficiency by excluding the impact of accounting depreciation. An analysis of the company's consolidated EBITDA allows for an assessment of financial stability and revenue predictability. In Oaktree Specialty Lending (OCS), this indicator confirms stability even amidst the automation of drug synthesis via AI. However, high costs for expert clinical trials create certain pressure on growth dynamics.

Competitors of Oaktree Specialty Lending (OCS)

Alcon Corp (ALC) - Profit before interest, taxes and amortization|Bausch + Lomb Corporation - Operating profit EBITDA|Profit before interest, taxes and amortization glaukos.com|Apellis (APLS) - Profit before payment of interest, taxes and amortization|BLTE - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Ocular Therapeutix Corp|Profit before interest, taxes and amortization Harrow Corp HROW|Operating profit EBITDA VRDN|Operating profit EBITDA lenz-tx.com (LENZ)|Profit before payment of interest, taxes and amortization EyePoint Pharmaceuticals, Inc. EYPT|Operating profit EBITDA Kodiak Sciences Inc KOD|ALDX: Operating profit before deduction of amortization|KALA BIO, Inc. - Company profit before taxes, interest and amortization|opusgtx.com (IRD) - Profit before payment of interest, taxes and amortization|OKYO Pharma - Income before deduction of interest, taxes and amortization|ADVM (Adverum Biotechnologies Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization Outlook Therapeutics Inc OTLK|Operating profit EBITDA CLSD|NBY - Profit before interest, taxes and amortization|Kiora Pharmaceuticals, Inc. - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization ALIM|EYEN - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Guardion Health Sciences, Inc. GHSI|Ocuphire (OCUP) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization OPT (Opthea Corp)